Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Current Vascular Pharmacology
Title: Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Volume: 3 Issue: 1
Author(s): Alex Agrotis, Natalia Kalinina and Alex Bobik
Affiliation:
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Abstract: Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Export Options
About this article
Cite this article as:
Agrotis Alex, Kalinina Natalia and Bobik Alex, Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773951
DOI https://dx.doi.org/10.2174/1570161052773951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Current Vascular Pharmacology Pregnancy, Physical Activity, Functional Capacity and Adaptations to Exercise
Current Women`s Health Reviews Mitochondria as Targets for Neuronal Protection Against Excitotoxicity: A Role for Phenolic Compounds?
Central Nervous System Agents in Medicinal Chemistry Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology An Integrated In Silico Method to Discover Novel Rock1 Inhibitors: Multi- Complex-Based Pharmacophore, Molecular Dynamics Simulation and Hybrid Protocol Virtual Screening
Combinatorial Chemistry & High Throughput Screening Emblica officinalis (Amla) Ameliorates High-Fat Diet Induced Alteration of Cardiovascular Pathophysiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances on the Antiatherogenic Effects of HDL-Derived Proteins and Mimetic Peptides
Current Pharmaceutical Design Editorial [Hot Topic:Modifying Cardiovascular Risk Factors: Newer Insights and Preventive Measures (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Structure of Atherosclerotic Plaques in Different Vascular Territories: Clinical Relevance
Current Vascular Pharmacology Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Therapies in Development for Non-Infectious Uveitis
Current Molecular Medicine The Involvement of Blood Coagulation Factor XIII in Fibrinolysis and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Progestins for Symptomatic Endometriosis: Results of Clinical Studies
Current Drug Therapy Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry